Overview Tiotropium/Salmeterol Inhalation Powder in COPD Status: Terminated Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined bt the SGRQ and the effect on COPD exacerbations Phase: Phase 3 Details Lead Sponsor: Boehringer IngelheimTreatments: Salmeterol XinafoateTiotropium Bromide